Ex­clu­sive: Liq­uid-biop­sy start­up clos­es $17M to fund ovar­i­an can­cer di­ag­nos­tic test

Liq­uid biop­sy start­up AOA Dx has col­lect­ed $17 mil­lion to sup­port the de­vel­op­ment of its di­ag­nos­tic test for ovar­i­an can­cer as well as the plat­form on which it is based.

The com­pa­ny’s di­ag­nos­tic plat­form, Gly­coLo­cate, is de­signed to de­tect cell sig­nal­ing mol­e­cules called gan­glio­sides in the blood. El­e­vat­ed lev­els are of­ten seen in can­cer pa­tients.

In Jan­u­ary, AOA Dx start­ed its prospec­tive study OVERT to in­ves­ti­gate its first di­ag­nos­tic test, AKRIV­IS GD, for ovar­i­an can­cer. The tri­al is re­cruit­ing across 20 US sites such as hos­pi­tals, gy­ne­col­o­gy and on­col­o­gy clin­ics, CEO Ori­ana Pa­pin-Zoghb told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER